Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | PRNP | P04156 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | CASR | P41180 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL39857 | 0.86 | ALDH1A1 (0.55) | HSD17B10ALDH1A1KDM4EHPGDMAPK1 | |
| SCHEMBL29730967 | 0.85 | RAB9A (0.45) | HSD17B10ALDH1A1KDM4EHPGDMAPK1 | |
| SCHEMBL13091554 | 0.85 | RAB9A (0.45) | HSD17B10ALDH1A1KDM4EHPGDMAPK1 | |
| Hydrochloric Acid SCHEMBL699717 | 0.84 | ALDH1A1 (0.53) | HSD17B10ALDH1A1KDM4EHPGDMAPK1 | |
| SCHEMBL184184 | 0.83 | LMNA (0.48) | HSD17B10ALDH1A1KDM4EHPGDHTT | |
| SCHEMBL29874691 | 0.83 | TSHR (0.49) | HSD17B10ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL257298 | 0.83 | TSHR (0.49) | HSD17B10ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL1515828 | 0.83 | HSD17B10 (0.43) | HSD17B10ALDH1A1KDM4EHTTALOX15 | |
| SCHEMBL78615 | 0.82 | PRNP (0.51) | HSD17B10ALDH1A1KDM4EHPGDMAPK1 | |
| SCHEMBL6215179 | 0.82 | HSD17B10 (0.55) | HSD17B10ALDH1A1KDM4EHPGDLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104870425-B | Method for synthesizing hydrazine for treating papilloma virus | 阿纳孔达药业公司 | 2017-06-13 | — | — | CN | claimed |
| US-12630541-B2 | Compounds useful as inhibitors of ALCAT 1 | PERENNA PHARMACEUTICALS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4603488-A1 | NOVEL INDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | Korea University Research and Business Foundation (KR) | 2025-08-20 | — | — | EP | disclosed |
| CN-120136858-A | Compounds useful as ALCAT1 inhibitors | 中美博瑞纳制药有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250179059-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| US-20250179000-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2025-06-05 | — | — | US | disclosed |
| CN-120035587-A | Novel indazole derivative or pharmaceutically acceptable salt thereof and use thereof | 高丽大学校产学协力团 | 2025-05-23 | — | — | CN | disclosed |
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119730846-A | Kinase modulators and methods of use thereof | 神经元23公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20250084056-A1 | SUBSTITUTED OXOISOINDOLINYL PIPERIDINE-2,6-DIONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-03-13 | — | — | US | disclosed |
| WO-2005073205-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050176684-A1 | Novel aryl fructose-1,6-bisphosphatase inhibitors | BOOKSER BRETT C (US) | 2005-08-11 | — | — | US | disclosed |
| CN-1652779-A | Combination therapy for chemokine mediated diseases | SCHERING CORP (US) | 2005-08-10 | — | — | CN | disclosed |
| US-6919322-B2 | Phenyl Phosphonate Fructose-1,6-Bisphosphatase Inhibitors | METABASIS THERAPEUTICS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1485089-A1 | COMBINATION TREATMENTS FOR CHEMOKINE-MEDIATED DISEASES | SCHERING CORPORATION (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040053953-A1 | Treatment of chemokine mediated diseases | SCHERING CORPORATION | 2004-03-18 | — | — | US | disclosed |
| WO-2003080053-A1 | COMBINATION TREATMENTS FOR CHEMOKINE-MEDIATED DISEASES | SCHERING CORPORATION (US) | 2003-10-02 | — | — | WO | disclosed |
| EP-1265907-A2 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | Metabasis Therapeutics, Inc. (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20020040014-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | METABASIS THERAPEUTICS, INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2001066553-A2 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | METABASIS THERAPEUTICS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084056-A1 | SUBSTITUTED OXOISOINDOLINYL PIPERIDINE-2,6-DIONE COMPOUNDS | CCNA1, CCNI, CCNE1 | HSD17B10 3304/4885ALDH1A1 431/4885KDM4E 1389/4885 |
| US-20250179059-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | HSD17B10 3192/4885ALDH1A1 3346/4885KDM4E 682/4885 |
| US-12630541-B2 | Compounds useful as inhibitors of ALCAT 1 | LCLAT1, LPCAT1, ACAT2 | HSD17B10 609/4885ALDH1A1 511/4885KDM4E 3151/4885 |
| US-20020040014-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | FBP1, SLC5A1, G6PC1 | HSD17B10 511/4885ALDH1A1 228/4885KDM4E 2245/4885 |
| US-20250179000-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | HSD17B10 3733/4885ALDH1A1 4468/4885KDM4E 2197/4885 |
| US-20040053953-A1 | Treatment of chemokine mediated diseases | CCR1, CXCR3, CCL11 | HSD17B10 1900/4885ALDH1A1 1161/4885KDM4E 4860/4885 |
| US-20050176684-A1 | Novel aryl fructose-1,6-bisphosphatase inhibitors | FBP1, G6PC1, SLC5A1 | HSD17B10 615/4885ALDH1A1 341/4885KDM4E 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.